RE:RE:RE:So let me get this straight Good question CHF and one that has puzzled me likewise.
Think that Sherri`s move to the States might have inadvertently complicated things.
What if everything relating to metal-based photo-sensitisers that she developed while still in Canada (including TLD-1433) can be commercialised by Theralase but with more recent developments (including the osmium compounds highlighted here) there is a caveat relating to the purported interests of individual US institutions or even parts of the US Government in respect of proprietary rights over what was developed by Sherri while at their particular establishments?
i.e.a potential stalemate with TLT restricted to to a still extensive market of superficial cancers (which would still include bladder, head and neck gynae and gullet) where TLD-1433 looks well suited but able to prevent anyone else using any of Sherri`s metal-based photosensitisers until 2054.
Such an impasse would suit Pharma fine but TLT`s ace in the hole could be Rutherrin - a compound they developed themselves from TLD-1433 and entirely outside restriction from elsewhere.
Rutherrin may be able to destroy deep tumours via x-ray activation and that is set to be tested in humans in the coming year. If it works Pharma could not just sit there and let it take big chunks of their market.
In the meantime and with what is at stake here would never under-estimate the degree to which there may be efforts to suppress this little Company and its`share price in any way possible.
Believe that the tie-up with Li Kai Shing has significantly strengthened Theralase`s hand with the market yet to register this.
Might be way wide of the mark and all MHO.